VERDOT

VERDOT, established in 1950 and headquartered in Riom, France, stands at the forefront of downstream bioprocessing technology. The company focuses on innovative purification solutions for the biopharmaceutical industry, including chromatography columns, and custom and standardized chromatography and tangential flow filtration (TFF) systems. VERDOT's systems and columns are employed in the purification, separation, and concentration of biomolecules such as monoclonal antibodies, vaccines, viral vectors (e.g., AAV and lentivirus), and mRNA-based therapeutics. VERDOT serves a diverse customer base, including research and development, early-stage biotech, biopharma, and contract development and manufacturing organizations (CDMOs) in all stages of the drug development workflow from exploration through the manufacturing of commercially available biologics. VERDOT's tailored, high-quality purification technologies empower their customers to accelerate time-to-market of groundbreaking and cost-effective therapies. The company's slogan, "Pure Progress. Tailored purification technologies through sustainable engineering," reflects its commitment to sustainable engineering practices in bioprocessing. As of now, there is no information available regarding the company's last investment or the investors involved. For further details about VERDOT, visit www.verdot-biotechnologies.com.